We are live on ! Find out more
PLRX icon

Pliant Therapeutics
PLRX

55 hedge funds and large institutions have $635M invested in Pliant Therapeutics in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

164% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 11

49% more funds holding

Funds holding: 37 → 55 (+18)

0.14% less ownership

Funds ownership: 79.7% → 79.56% (-0.14%)

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

28% less capital invested

Capital invested by funds: $877M → $635M (-$242M)

Holders
55
Holders Change
+18
Holders Change %
+48.65%
% of All Funds
1.11%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.06%
New
29
Increased
7
Reduced
9
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$10.4M
2
BlackRock
BlackRock
New York
+$9.97M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$4.84M
4
WP
Woodline Partners
California
+$3.8M
5
Northern Trust
Northern Trust
Illinois
+$3.03M

Top Sellers

1
LGM
Logos Global Management
California
-$7.99M
2
SCM
Suvretta Capital Management
New York
-$3.07M
3
ZP
Zimmer Partners
New York
-$2.78M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
-$2.6M
5
FCM
Farallon Capital Management
California
-$2.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
TGI
1
TRV GP III
Massachusetts
$132M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$120M -$404K -16,185 -0.3%
RG
3
Redmile Group
California
$76.8M -$472K -18,900 -0.6%
EAM
4
Eventide Asset Management
Massachusetts
$61.7M – – –
CA
5
CHI Advisors
New York
$53.3M +$1.16M +46,297 +2%
TGI
6
TRV GP IV
Massachusetts
$48.3M – – –
Citadel Advisors
7
Citadel Advisors
Florida
$27.8M -$83.6K -3,347 -0.3%
FCM
8
Farallon Capital Management
California
$17.3M -$2.16M -86,539 -10%
CAM
9
Cormorant Asset Management
Massachusetts
$13.6M – – –
HMC
10
Harvard Management Company
Massachusetts
$12.7M – – –
Bessemer Group
11
Bessemer Group
New Jersey
$12.2M – – –
BlackRock
12
BlackRock
New York
$11M +$9.97M +398,792 +466%
Vanguard Group
13
Vanguard Group
Pennsylvania
$9.99M +$10.4M +415,993 +1,664%
Franklin Resources
14
Franklin Resources
California
$7.93M – – –
Lord, Abbett & Co
15
Lord, Abbett & Co
New Jersey
$4.39M +$4.84M +193,706 New
WP
16
Woodline Partners
California
$3.44M +$3.8M +152,000 New
LGM
17
Logos Global Management
California
$3.1M -$7.99M -319,711 -70%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$3.06M +$2.91M +116,579 +630%
Northern Trust
19
Northern Trust
Illinois
$2.75M +$3.03M +121,214 New
State Street
20
State Street
Massachusetts
$2.72M +$3M +120,207 New
Bank of New York Mellon
21
Bank of New York Mellon
New York
$1.95M +$1.65M +66,048 +328%
Charles Schwab
22
Charles Schwab
California
$1.43M +$1.57M +63,012 New
Point72 Asset Management
23
Point72 Asset Management
Connecticut
$1.17M +$1.29M +51,500 New
PCM
24
Pentwater Capital Management
Florida
$917K – – –
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
$853K +$941K +37,667 New
1
2 3

PLRX Hedge Fund Activity: Q3 2020 in Review

55 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q3 2020, worth a combined $635M — down 28% from $877M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new PLRX positions and 11 closed out — a net gain of 18 holders — while 7 added to existing stakes and 9 trimmed.

The largest buyer was Vanguard Group, adding an estimated $10.4M. The largest seller was Logos Global Management, cutting an estimated $7.99M.

  • 55 institutional investors held Pliant Therapeutics (PLRX) as of Q3 2020, up from 37 in Q2 2020.
  • Funds reported $635M of Pliant Therapeutics stock for Q3 2020, down 28% quarter-over-quarter.
  • 29 funds opened new Pliant Therapeutics positions in Q3 2020 and 11 closed out, a net change of +18 holders.
  • The largest Pliant Therapeutics buyer in Q3 2020 was Vanguard Group, an estimated $10.4M added.
  • The largest Pliant Therapeutics seller in Q3 2020 was Logos Global Management, an estimated $7.99M sold.

Based on aggregated 13F filings for Q3 2020.